Report #2865536

Received Oct 13, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: 71 yrs
State: NC
Recovered: Unknown
Vaccinated: Oct 2, 2025
Onset: Oct 2, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
RSV	RSV (AREXVY)	GLAXOSMITHKLINE BIOLOGICALS	2	B5NJ9	—

Symptoms (1)

Extra dose administered

Symptom narrative

Extra dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a elderly male patient who received RSVPreF3 adjuvanted (Arexvy) (batch number B5NJ9, expiry date 05-DEC-2026) for prophylaxis. Previously administered products included Arexvy (Received 1st dose of Arexvy vaccine on 25-OCT-2023). On 02-OCT-2025, the patient received the 2nd dose of Arexvy. On 02-OCT-2025, an unknown time after receiving Arexvy, the patient experienced extra dose administered (Verbatim: Extra dose). The outcome of the extra dose administered was not applicable.